Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?

Arteaga CL
Clin Cancer Res. 2011 17 (15): 4919-21

PMID: 21670086 · PMCID: PMC3221729 · DOI:10.1158/1078-0432.CCR-11-1218

Inhibition of the HSP90 chaperone leads to degradation of the HER2 receptor. The HSP90 inhibitor tanespimycin in combination with trastuzumab is active in patients with HER2-overexpressing metastatic breast cancer. This combination is one of several HER2-targeted therapies that will significantly improve the outcome of patients with this subtype of breast cancer.

©2011 AACR.

MeSH Terms (11)

Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Benzoquinones Breast Neoplasms Female Genes, erbB-2 HSP90 Heat-Shock Proteins Humans Lactams, Macrocyclic Male Trastuzumab

Connections (1)

This publication is referenced by other Labnodes entities: